The FDA recently approved romosozumab for high risk post menopausal osteoporosis, but gave it a black box warning for cardiovascular disease.  This week I'll cover the data that led to it's approval despite such dire warnings.  

Get the papers themselves here and be sure to follow the podcast on twitter @ebrheum or sign up with your favorite podcast aggregator at ebrheum.com